CryoPort (NASDAQ:CYRX) Stock: Insider Mark Sawicki Sells 10,000 Shares

CryoPort, Inc. (NASDAQ:CYRX – Get Free Report) insider Mark Sawicki sold 10,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $19.93, for a total value of $199,300.00. Following the completion of the sale, the insider directly owned 92,356 shares in the company, valued at approximately $1,840,655.08. This represents a 9.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

CryoPort Stock Down 1.0%

Shares of CYRX traded down $0.21 during midday trading on Friday, hitting $19.89. The company’s stock had a trading volume of 406,849 shares, compared to its average volume of 1,284,760. CryoPort, Inc. has a one year low of $7.61 and a one year high of $21.78. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -20.50 and a beta of 1.89. The company’s fifty day simple moving average is $17.43 and its two-hundred day simple moving average is $13.70.

CryoPort (NASDAQ:CYRX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The business had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. CryoPort had a negative return on equity of 8.28% and a negative net margin of 21.46%. On average, research analysts predict that CryoPort, Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CYRX. BTIG Research increased their target price on shares of CryoPort from $25.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Guggenheim lifted their price target on shares of CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Needham & Company LLC lifted their price target on shares of CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 6th. Weiss Ratings upgraded shares of CryoPort from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Finally, Piper Sandler raised shares of CryoPort to a “buy” rating in a research note on Tuesday, October 13th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, CryoPort presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.69.

View Our Latest Research Report on CryoPort

Institutional Investors Weigh In On CryoPort

Hedge funds and other institutional investors have recently bought and sold shares of the company. Roubaix Capital LLC increased its holdings in CryoPort by 12.4% in the 3rd quarter. Roubaix Capital LLC now owns 454,926 shares of the company’s stock worth $7,916,000 after purchasing an additional 50,148 shares in the last quarter. White Pine Capital LLC acquired a new stake in shares of CryoPort during the third quarter valued at about $539,000. Royce & Associates LP acquired a new stake in shares of CryoPort during the third quarter valued at about $7,073,000. Diversified Trust Co grew its holdings in shares of CryoPort by 3.4% during the third quarter. Diversified Trust Co now owns 19,769 shares of the company’s stock worth $344,000 after purchasing an additional 657 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its holdings in shares of CryoPort by 376.7% during the third quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock worth $6,943,000 after purchasing an additional 315,343 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

CryoPort Company Profile

(Get Free Report)

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.

Featured Articles

Insider Buying and Selling by Quarter for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.